4D Molecular Therapeutics, Inc. — All Filings
385 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
144/A
3
3/A
4
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
EFFECT
FWP
POS AM
POSASR
RW
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-8
S-8 POS
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | 4 | 0000950170-25-088496 | Jun 20, 2025 | Jun 17, 2025 |
| 4 | 4 | 0000950170-25-088487 | Jun 20, 2025 | Jun 17, 2025 |
| SCHEDULE 13G/A | — | 0000921895-25-001547 | May 15, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-013259 | May 15, 2025 | — |
| 8-K | 8-K | 0000950170-25-067013 | May 8, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-067040 | May 8, 2025 | Mar 31, 2025 |
| S-8 | S-8 | 0001193125-25-116018 | May 8, 2025 | — |
| DEFA14A | DEFA14A | 0001140361-25-016320 | Apr 29, 2025 | — |
| ARS | ARS | 0001140361-25-016323 | Apr 29, 2025 | Dec 31, 2024 |
| DEF 14A | DEF 14A | 0001140361-25-016307 | Apr 29, 2025 | Jun 17, 2025 |
| SCHEDULE 13G/A | — | 0001576419-25-000599 | Apr 17, 2025 | — |
| EFFECT | — | 9999999995-25-000737 | Mar 24, 2025 | — |
| 4 | 4 | 0000950170-25-036686 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | 4 | 0000950170-25-036688 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | 4 | 0000950170-25-036696 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | 4 | 0000950170-25-036685 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | 4 | 0000950170-25-036683 | Mar 10, 2025 | Mar 6, 2025 |
| S-8 | S-8 | 0001193125-25-042758 | Feb 28, 2025 | — |
| POS AM | POS AM | 0001193125-25-042780 | Feb 28, 2025 | — |
| POSASR | POSASR | 0001193125-25-042482 | Feb 28, 2025 | — |
| 8-K | 8-K | 0000950170-25-030020 | Feb 28, 2025 | — |
| 10-K | 10-K | 0000950170-25-030056 | Feb 28, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | — | 0001415889-25-004273 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0000921895-25-000489 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001172661-25-000872 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-004236 | Feb 14, 2025 | — |
| 8-K | 8-K | 0000950170-25-016708 | Feb 10, 2025 | Feb 8, 2025 |
| 8-K | 8-K | 0000950170-25-003832 | Jan 10, 2025 | — |
| 8-K | 8-K | 0000950170-24-135381 | Dec 11, 2024 | Dec 6, 2024 |
| 4 | — | 0001415889-24-028837 | Dec 10, 2024 | Dec 9, 2024 |
| SC 13G/A | — | 0002012383-24-004549 | Dec 6, 2024 | — |
| 3 | — | 0001415889-24-027636 | Nov 25, 2024 | Nov 13, 2024 |
| SC 13G/A | SC 13G/A | 0001104659-24-119770 | Nov 15, 2024 | — |
| SC 13G/A | — | 0001172661-24-004728 | Nov 14, 2024 | — |
| SC 13G/A | — | 0000905148-24-003166 | Nov 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-119280 | Nov 14, 2024 | — |
| 8-K | 8-K | 0000950170-24-126346 | Nov 13, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-126370 | Nov 13, 2024 | Sep 30, 2024 |
| 4 | OWNERSHIP DOCUMENT | 0000921895-24-002631 | Nov 13, 2024 | Nov 8, 2024 |
| SC 13G/A | AMENDMENT NO. 3 TO SCHEDULE 13G | 0000921895-24-002625 | Nov 13, 2024 | — |
| SC 13G/A | — | 0000932471-24-000815 | Nov 12, 2024 | — |
| SC 13G/A | — | 0002012383-24-003680 | Nov 8, 2024 | — |
| SC 13G | — | 0000932471-24-000236 | Nov 4, 2024 | — |
| SC 13G/A | — | 0002012383-24-000961 | Oct 21, 2024 | — |
| 8-K | 8-K | 0001193125-24-221375 | Sep 18, 2024 | — |
| 4 | 4 | 0000950170-24-107903 | Sep 18, 2024 | Sep 16, 2024 |
| 4 | 4 | 0000950170-24-099505 | Aug 21, 2024 | Aug 19, 2024 |
| 8-K | 8-K | 0000950170-24-093992 | Aug 8, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-094010 | Aug 8, 2024 | Jun 30, 2024 |
| 3 | OWNERSHIP DOCUMENT | 0000921895-24-001663 | Aug 1, 2024 | Jul 22, 2024 |